EUDA Signs Letter of Intent to Potentially Acquire GO POSB

Rhea-AI Summary

EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has signed a Letter of Intent to potentially acquire GO POSB Organoids, a Singapore biotechnology company. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that converts human blood cells into clinical-grade stem cells.

The companies plan to establish an iPSC laboratory and cultivation facility in Shenzhen, China, collaborating with Singapore's A*STAR for research and clinical trials. The facility aims to serve as a distribution hub for iPSC solutions across China, pending regulatory approvals. The initiative aligns with EUDA's strategy to expand its stem cell treatments and supplements portfolio.

Positive

• Strategic expansion into the promising iPSC biotechnology sector
• Potential to establish a state-of-the-art iPSC facility in Shenzhen, China
• Partnership with Singapore's A*STAR for research and clinical trials
• Access to B2B opportunities in healthcare ecosystem and wellness markets

Negative

• Acquisition is still in LOI phase with no guaranteed completion
• Requires significant regulatory approvals in China
• No financial terms or investment requirements disclosed
• Implementation and facility development timeline uncertainties

SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has signed a Letter of Intent (the “LOI”) to potentially acquire GO POSB Organoids Pte Ltd (“GO POSB”), a biotechnology company formed in Singapore.

GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells. These iPSCs can differentiate into nearly any cell type in the human body, unlocking applications in drug discovery, disease modelling, regenerative medicine, and future cell-based therapies. Importantly, iPSCs provide pluripotency without the ethical concerns linked to embryonic stem cells, making them one of the most promising frontiers in biotechnology.

Strategic Expansion into iPSC Solutions

Under the LOI, EUDA and GO POSB are exploring the establishment of a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China. The facility would serve as a hub to store, expand, and distribute iPSC solutions to hospitals, clinics, and research centers across China, subject to regulatory approvals. EUDA will provide funding for the build-out while the two companies collaborate with Singapore’s Agency for Science, Technology and Research (A*STAR) to advance iPSC research, conduct clinical trials, and accelerate regulatory pathways for therapeutic applications.

The collaboration will position EUDA to supply B2B iPSC solutions to the downstream healthcare ecosystem, including hospitals, regenerative clinics, and biotech developers. Beyond core therapeutic applications, the platform also opens future opportunities for off-the-shelf iPSC-derived product lines tailored for Asia’s wellness and aesthetics markets, such as iPSC-based hair rejuvenation and facial treatments. These initiatives are designed to directly complement EUDA’s growing portfolio of stem cell treatments and supplements, reinforcing the Company’s integrated approach to longevity and regenerative health.

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Go POSB, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Christensen Advisory

Linda Bergkamp

Phone: +1-480-614-3004

E-mail: linda.bergkamp@christensencomms.com

FAQ

What is the purpose of EUDA's potential acquisition of GO POSB?

EUDA aims to acquire GO POSB to expand into the iPSC biotechnology sector, leveraging GO POSB's proprietary platform that converts human blood cells into clinical-grade stem cells for various therapeutic applications.

What are the main features of GO POSB's iPSC technology?

GO POSB's technology can reprogram human blood cells into clinical-grade, therapeutics-ready stem cells that can differentiate into nearly any cell type, with applications in drug discovery, disease modeling, and regenerative medicine.

Where will EUDA and GO POSB establish their iPSC facility?

The companies plan to establish a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China, serving as a hub for storing, expanding, and distributing iPSC solutions.

What is the current status of EUDA's acquisition of GO POSB?

EUDA has signed a Letter of Intent (LOI) for the potential acquisition, indicating the deal is in preliminary stages and subject to further negotiation and completion.

How does this acquisition align with EUDA's business strategy?

The acquisition complements EUDA's growing portfolio of stem cell treatments and supplements, reinforcing their integrated approach to longevity and regenerative health while expanding into the B2B healthcare ecosystem.